Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 16, Issue 2

March-April 2019

In this Issue

Ask the Hematologist
Clinical Trials Corner
Diffusion
Features
Headlines from Washington
In Memoriam
No Data Zone
President’s Column

Ask the Hematologist

Ask the Hematologist: Recruiting Residents to Become Hematologists

Marc J. Kahn, MD, MBA

View Articletitled, Ask the Hematologist: Recruiting Residents to Become Hematologists

Clinical Trials Corner

Treatment of Renally Impaired Patients With Venous Thromboembolism: Awaiting the VERDICT

Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC

View Articletitled, Treatment of Renally Impaired Patients With Venous Thromboembolism: Awaiting the VERDICT

JAKing Up Targeted Therapy for Ph-like Acute Lymphoblastic Leukemia

Yang-Yang Ding, MD,David T. Teachey, MD

View Articletitled, JAKing Up Targeted Therapy for Ph-like Acute Lymphoblastic Leukemia

Diffusion

Hydroxyurea for Children With Sickle Cell Anemia in Sub-Saharan Africa: The Child That Comes and Goes Away Can Come to Stay With Hydroxyurea

Ifeyinwa (Ify) Osunkwo, MD, MPH

View Articletitled, Hydroxyurea for Children With Sickle Cell Anemia in Sub-Saharan Africa: The Child That Comes and Goes Away Can Come to Stay With Hydroxyurea

Comprehensive Genomic Classification of Pediatric Mixed-Phenotype Acute Leukemia

Michael W. Becker, MD,Kristen M. O'Dwyer, MD

View Articletitled, Comprehensive Genomic Classification of Pediatric Mixed-Phenotype Acute Leukemia

A New Standard Emerges: Rational Use of Venetoclax to Inhibit BCL-2 Allows Treatment of AML In Older Patients

Amy DeZern, MD, MHS

View Articletitled, A New Standard Emerges: Rational Use of Venetoclax to Inhibit BCL-2 Allows Treatment of AML In Older Patients

Keeping Your ESCHELONs Straight

Brad Kahl, MD

View Articletitled, Keeping Your ESCHELONs Straight

Defining the Poor Prognosis of Double-Hit Lymphomas: Implications for Diagnosis and Therapy

Caron A. Jacobson, MD

View Articletitled, Defining the Poor Prognosis of Double-Hit Lymphomas: Implications for Diagnosis and Therapy

The Microbiome: A New Variable in Multiple Myeloma Disease Progression

Yujia Shen, PhD,Romanos Sklavenitis Pistofidis, MD,Irene M. Ghobrial, MD

View Articletitled, The Microbiome: A New Variable in Multiple Myeloma Disease Progression

The Cellular Pathway of Leukemic Transformation in MDS: It's the Stem Cells, Stupid!

Alba Rodriguez-Meira, DPhil,Adam Mead, MD, PhD

View Articletitled, The Cellular Pathway of Leukemic Transformation in MDS: It's the Stem Cells, Stupid!

Beating AML: Know Your Enemy

Steven Lane, MBBS, PhD, FRACP, FRCPA

View Articletitled, Beating AML: Know Your Enemy

Monitoring Treatment Response in Multiple Myeloma: Wading Into the Deep End

Madhu M. Ouseph, MD, PhD,Annette S. Kim, MD, PhD

View Articletitled, Monitoring Treatment Response in Multiple Myeloma: Wading Into the Deep End

Thromboprophylaxis in Ambulatory Cancer Patients: Results of the AVERT Trial

Jori May, MD,Stephan Moll, MD

View Articletitled, Thromboprophylaxis in Ambulatory Cancer Patients: Results of the AVERT Trial

Features

Real World Data on CAR T-Cell Recipients: Are We There Yet?

Miguel-Angel Perales, MD,Marcelo C. Pasquini, MD, MS

View Articletitled, Real World Data on CAR T-Cell Recipients: Are We There Yet?

Pulmonary Embolism Response Teams: Structuring a Dedicated Provider Response to Improve Outcomes for Patients and Institutions

Roy Smith, MD, MS,Rachel Rosovsky, MD, MPH

View Articletitled, Pulmonary Embolism Response Teams: Structuring a Dedicated Provider Response to Improve Outcomes for Patients and Institutions

An Unusual Consult

Stephan Moll, MD

View Articletitled, An Unusual Consult

Headlines from Washington

Government Affairs Committee Chair Speaks on the Need for Advocacy in the New Congress

ASH Staff

View Articletitled, Government Affairs Committee Chair Speaks on the Need for Advocacy in the New Congress

In Memoriam

Peter Robert Galbraith, MD, FRCPC (1931-2018)

View Articletitled, Peter Robert Galbraith, MD, FRCPC (1931-2018)

Sir David Weatherall, MD, FRCP, FRS (1933-2018)

View Articletitled, Sir David Weatherall, MD, FRCP, FRS (1933-2018)

No Data Zone

Transplantation and Myelofibrosis: A Little Medicine and a Little Art

Jeanne Palmer, MD,Tania Jain, MBBS

View Articletitled, Transplantation and Myelofibrosis: A Little Medicine and a Little Art

President’s Column

In the Interest of Transparency

Roy L. Silverstein, MD

View Articletitled, In the Interest of Transparency

Cover Image

Cover Image

All Issues

Advertisement intended for health care professionals

Email alerts

Latest Issue Alert

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read

Vitamin A to Keep GVHD Away: Single Oral High-Dose Vitamin A Before Bone Marrow Transplant Reduces Graft-Versus-Host Disease in Pediatric and Young Adult Patients

Trainee Corner
A Career in Academia: Should I Stay or Should I Go?

Then and Now
Treatment for Acute Leukemia in Older Adults: Two Decades of Remarkable Progress

Does Sustained Monocytosis Always Mean CMML? A Case of Ras-Associated Autoimmune Leukoproliferative Disorder

ASH and Federal Officials Hold Town Hall on Sickle Cell Disease

Advertisement intended for health care professionals

Table of Contents

Ask the Hematologist

Ask the Hematologist: Recruiting Residents to Become Hematologists

Clinical Trials Corner

Treatment of Renally Impaired Patients With Venous Thromboembolism: Awaiting the VERDICT

JAKing Up Targeted Therapy for Ph-like Acute Lymphoblastic Leukemia

Diffusion

Hydroxyurea for Children With Sickle Cell Anemia in Sub-Saharan Africa: The Child That Comes and Goes Away Can Come to Stay With Hydroxyurea

Comprehensive Genomic Classification of Pediatric Mixed-Phenotype Acute Leukemia

A New Standard Emerges: Rational Use of Venetoclax to Inhibit BCL-2 Allows Treatment of AML In Older Patients

Keeping Your ESCHELONs Straight

Defining the Poor Prognosis of Double-Hit Lymphomas: Implications for Diagnosis and Therapy

The Microbiome: A New Variable in Multiple Myeloma Disease Progression

The Cellular Pathway of Leukemic Transformation in MDS: It's the Stem Cells, Stupid!

Beating AML: Know Your Enemy

Monitoring Treatment Response in Multiple Myeloma: Wading Into the Deep End

Thromboprophylaxis in Ambulatory Cancer Patients: Results of the AVERT Trial

Features

Real World Data on CAR T-Cell Recipients: Are We There Yet?

Pulmonary Embolism Response Teams: Structuring a Dedicated Provider Response to Improve Outcomes for Patients and Institutions

An Unusual Consult

Headlines from Washington

Government Affairs Committee Chair Speaks on the Need for Advocacy in the New Congress

In Memoriam

Peter Robert Galbraith, MD, FRCPC (1931-2018)

Sir David Weatherall, MD, FRCP, FRS (1933-2018)

No Data Zone

Transplantation and Myelofibrosis: A Little Medicine and a Little Art

President’s Column

In the Interest of Transparency

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

Ask the Hematologist

Clinical Trials Corner

Diffusion

Features

Headlines from Washington

In Memoriam

No Data Zone

President’s Column

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only